866-997-4948(US-Canada Toll Free)

Small-Cell Lung Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 348 Pages

Small-Cell Lung Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H2 2014, provides an overview of the Small-Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Small-Cell Lung Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Small-Cell Lung Cancer - Overview 12
Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis 13
Small-Cell Lung Cancer - Therapeutics under Development by Companies 14
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 19
Small-Cell Lung Cancer - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Small-Cell Lung Cancer - Products under Development by Companies 24
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 26
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 27
Bristol-Myers Squibb Company 27
Johnson & Johnson 28
Boehringer Ingelheim GmbH 29
Amgen Inc. 30
AstraZeneca PLC 31
Eli Lilly and Company 32
GlaxoSmithKline plc 33
Nektar Therapeutics 34
Merck & Co., Inc. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
Aposense Ltd. 37
ZIOPHARM Oncology, Inc. 38
Millennium Pharmaceuticals, Inc. 39
Novartis AG 40
Astellas Pharma Inc. 41
Nippon Kayaku Co., Ltd. 42
Pfizer Inc. 43
Taiho Pharmaceutical Co., Ltd. 44
Vertex Pharmaceuticals Incorporated 45
Onyx Pharmaceuticals, Inc. 46
Bayer AG 47
Alchemia Limited 48
ImmunoCellular Therapeutics, Ltd. 49
Immunomedics, Inc. 50
MEI Pharma, Inc. 51
Critical Outcome Technologies Inc. 52
Topotarget A/S 53
CytRx Corporation 54
Mologen AG 55
Synta Pharmaceuticals Corp. 56
MabVax Therapeutics, Inc. 57
Spectrum Pharmaceuticals, Inc. 58
Supratek Pharma Inc. 59
Oxford BioTherapeutics Ltd 60
TheRyte Ltd. 61
Celator Pharmaceuticals, Inc. 62
Cerulean Pharma, Inc. 63
Merrimack Pharmaceuticals, Inc. 64
Neotropix, Inc. 65
Mersana Therapeutics, Inc. 66
Cornerstone Pharmaceuticals, Inc. 67
Omnitura Therapeutics Inc. 68
MolMed S.p.A. 69
Laboratorios Farmaceuticos Rovi, S.A. 70
Recombio 71
Polaris Group 72
CellAct Pharma GmbH 73
Tesaro, Inc. 74
Verastem, Inc. 75
Zensun (Shanghai) Sci & Tech Co., Ltd. 76
Inbiopro Solutions Pvt. Ltd. 77
AbbVie Inc. 78
Small-Cell Lung Cancer - Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Target 81
Assessment by Mechanism of Action 86
Assessment by Route of Administration 92
Assessment by Molecule Type 94
Drug Profiles 97
amrubicin hydrochloride - Drug Profile 97
ipilimumab - Drug Profile 99
amrubicin hydrochloride - Drug Profile 102
palifosfamide - Drug Profile 104
sabarubicin - Drug Profile 106
ipilimumab - Drug Profile 108
alisertib - Drug Profile 111
vandetanib - Drug Profile 115
irinotecan hydrochloride - Drug Profile 121
etirinotecan pegol - Drug Profile 123
NTX-010 - Drug Profile 125
CPI-613 - Drug Profile 127
carfilzomib - Drug Profile 129
NGR-hTNF - Drug Profile 132
ganetespib - Drug Profile 135
(tipiracil + trifluridine) - Drug Profile 139
nintedanib - Drug Profile 141
CRLX-101 - Drug Profile 144
MGN-1703 - Drug Profile 146
pegargiminase - Drug Profile 148
MK-2206 + selumetinib sulfate - Drug Profile 151
NK-012 - Drug Profile 152
temozolomide - Drug Profile 154
roniciclib - Drug Profile 156
LY-2510924 - Drug Profile 158
IMMU-132 - Drug Profile 159
bemiparin sodium - Drug Profile 160
CAP-7.1 - Drug Profile 162
VX-970 - Drug Profile 164
MX-225 - Drug Profile 165
rilotumumab - Drug Profile 166
ganitumab - Drug Profile 168
TF-2 - Drug Profile 171
nivolumab - Drug Profile 173
taladegib - Drug Profile 177
tarextumab - Drug Profile 178
SC-16LD6.5 - Drug Profile 180
solitomab - Drug Profile 181
topotecan hydrochloride liposomal - Drug Profile 183
BMS-833923 - Drug Profile 184
JNJ-42756493 - Drug Profile 186
aldoxorubicin - Drug Profile 188
belinostat - Drug Profile 190
XMT-1001 - Drug Profile 193
racotumomab - Drug Profile 195
P-2045 - Drug Profile 197
erismodegib - Drug Profile 198
Cell Therapy 1 for Oncology - Drug Profile 200
Small Cell Lung Cancer Vaccine - Drug Profile 201
ME-344 - Drug Profile 202
GSK-2879552 - Drug Profile 204
OSI-930 - Drug Profile 205
ICT-109 - Drug Profile 206
COTI-2 - Drug Profile 208
irinotecan sucrosofate liposomal - Drug Profile 211
topotecan hydrochloride nanoformulation - Drug Profile 213
ATT-11T - Drug Profile 214
OMN-54 - Drug Profile 215
TRBS-07 - Drug Profile 217
ABT-737 - Drug Profile 218
Adva-27a - Drug Profile 220
COTI-219 - Drug Profile 222
(irinotecan hydrochloride + cisplatin) - Drug Profile 223
ZS-05 - Drug Profile 225
IBPM-002BZ - Drug Profile 226
VS-5584 - Drug Profile 227
TAS-116 - Drug Profile 228
Cyt-PLAT - Drug Profile 229
Synthetic Peptide to Antagonize Neurotensin Receptor 1 for Cancer - Drug Profile 230
OX-025 - Drug Profile 231
PF-4989216 - Drug Profile 232
Monoclonal Antibodies to Inhibit Vasopressin V2 Receptor for Small-Cell Lung Cancer - Drug Profile 233
HDC-SN-38 - Drug Profile 234
HDC-Docetaxel - Drug Profile 236
COTI-4 - Drug Profile 237
COTI-58 - Drug Profile 238
Small Molecules for Small Cell Lung Cancer - Drug Profile 239
etoposide phosphate reformulation - Drug Profile 240
Small Molecules to Inhibit EZH2-EED Cancer - Drug Profile 242
THR-53 - Drug Profile 243
niraparib - Drug Profile 244
Synthetic Peptide to Agonize VIP for Small Cell Lung Cancer - Drug Profile 246
Small-Cell Lung Cancer - Recent Pipeline Updates 247
Small-Cell Lung Cancer - Dormant Projects 334
sSmall-Cell Lung Cancer - Discontinued Products 334
Small-Cell Lung Cancer - Discontinued Products 335
Small-Cell Lung Cancer - Product Development Milestones 336
Featured News & Press Releases 336
Appendix 342
Methodology 342
Coverage 342
Secondary Research 342
Primary Research 342
Expert Panel Validation 342
Contact Us 343
Disclaimer 343

List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H2 2014 17
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Development, H2 2014 27
Comparative Analysis by Unknown Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Investigation by Universities/Institutes, H2 2014 31
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 32
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2014 33
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 34
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H2 2014 35
Small-Cell Lung Cancer - Pipeline by AstraZeneca PLC, H2 2014 36
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2014 37
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 38
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2014 39
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H2 2014 40
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 41
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H2 2014 42
Small-Cell Lung Cancer - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 43
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 44
Small-Cell Lung Cancer - Pipeline by Novartis AG, H2 2014 45
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H2 2014 46
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 47
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H2 2014 48
Small-Cell Lung Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 49
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 50
Small-Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 51
Small-Cell Lung Cancer - Pipeline by Bayer AG, H2 2014 52
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H2 2014 53
Small-Cell Lung Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 54
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H2 2014 55
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H2 2014 56
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 57
Small-Cell Lung Cancer - Pipeline by Topotarget A/S, H2 2014 58
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H2 2014 59
Small-Cell Lung Cancer - Pipeline by Mologen AG, H2 2014 60
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 61
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics, Inc., H2 2014 62
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 63
Small-Cell Lung Cancer - Pipeline by Supratek Pharma Inc., H2 2014 64
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 65
Small-Cell Lung Cancer - Pipeline by TheRyte Ltd., H2 2014 66
Small-Cell Lung Cancer - Pipeline by Celator Pharmaceuticals, Inc., H2 2014 67
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 68
Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 69
Small-Cell Lung Cancer - Pipeline by Neotropix, Inc., H2 2014 70
Small-Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2014 71
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 72
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 73
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H2 2014 74
Small-Cell Lung Cancer - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2014 75
Small-Cell Lung Cancer - Pipeline by Recombio, H2 2014 76
Small-Cell Lung Cancer - Pipeline by Polaris Group, H2 2014 77
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2014 78
Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H2 2014 79
Small-Cell Lung Cancer - Pipeline by Verastem, Inc., H2 2014 80
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 81
Small-Cell Lung Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 82
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2014 83
Assessment by Monotherapy Products, H2 2014 84
Assessment by Combination Products, H2 2014 85
Number of Products by Stage and Target, H2 2014 88
Number of Products by Stage and Mechanism of Action, H2 2014 93
Number of Products by Stage and Route of Administration, H2 2014 98
Number of Products by Stage and Molecule Type, H2 2014 101
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2014 252
Small-Cell Lung Cancer - Dormant Projects, H2 2014 339
Small-Cell Lung Cancer - Discontinued Products, H2 2014 340

List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H2 2014 17
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 19
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Products, H2 2014 27
Assessment by Monotherapy Products, H2 2014 84
Assessment by Combination Products, H2 2014 85
Number of Products by Top 10 Target, H2 2014 86
Number of Products by Stage and Top 10 Target, H2 2014 87
Number of Products by Top 10 Mechanism of Action, H2 2014 91
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 92
Number of Products by Top 10 Route of Administration, H2 2014 97
Number of Products by Stage and Top 10 Route of Administration, H2 2014 98
Number of Products by Top 10 Molecule Type, H2 2014 99
Number of Products by Stage and Top 10 Molecule Type, H2 2014 100

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *